Investor Presentation
|
|
- Sarah Grant
- 5 years ago
- Views:
Transcription
1 Investor Presentation James Sapirstein, CEO NASDAQ: CTRV
2 Safe Harbor Statement This presentation may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of Such forwardlooking statements are characterized by future or conditional verbs such as may, will, expect, intend, anticipate, believe, estimate and continue or similar words. You should read statements that contain these words carefully because they discuss future expectations and plans, which contain projections of future results of operations or financial condition or state other forwardlooking information. Such statements are only predictions and our actual results may differ materially from those anticipated in these forward-looking statements. We believe that it is important to communicate future expectations to investors. However, there may be events in the future that we are not able to accurately predict or control. Factors that may cause such differences include, but are not limited to, those discussed under Risk Factors in our periodic reports filed with the Securities and Exchange Commission, including the uncertainties associated with product development, the risk that products that appeared promising in early clinical trials do not demonstrate safety and efficacy in larger-scale clinical trials, the risk that we will not obtain approval to market our products, the risks associated with dependence upon key personnel and the need for additional financing. We do not assume any obligation to update forward-looking statements as circumstances change. This presentation does not constitute an offer or invitation for the sale or purchase of securities or to engage in any other transaction with ContraVir or its affiliates. The information in this presentation is not targeted at the residents of any particular country or jurisdiction and is not intended for distribution to, or use by, any person in any jurisdiction or country where such distribution or use would be contrary to local law or regulation. 1
3 Corporate Overview Company Profile Advanced clinical stage drug development company with a Virology focus Value Drivers CMX157: Novel, high potency lipid conjugate of tenofovir for treating Hepatitis B Phase 1b/2a trials ongoing CRV431: Novel, high potency cyclophilin inhibitor for treating Hepatitis B Preparing for pre-ind studies FV-100: Reduced shingles-associated, post-herpetic neuralgia (PHN) in Phase 2 trials Phase 3 trial ongoing Seeking to create a diversified and complementary virology pipeline Preclinical Phase 1 Phase 2 Phase 3 CMX157 CRV431 FV-100 Hepatitis B Hepatitis B Shingles and PHN 2
4 Experienced Leadership Leadership History James Sapirstein, R.Ph. Chief Executive Officer 30+ years bio/pharma experience, including leading six product launches Key in the development and launch of tenofovir John Cavan Chief Financial Officer 20+ years financial management experience at both public and private companies Financial/operational positions at large multinational companies John Sullivan-Bólyai, M.D., MPH Chief Medical Officer 25+ years antiviral development experience in all four clinical phases, focused on HCV and HBV Key in the filing of four successful NDAs Robert Foster, Pharm.D., Ph.D. Chief Scientific Officer 30+ years of pharmaceutical discovery and development Track record of successful biotechnology entrepreneurship Theresa Matkovits, Ph.D. Senior Vice President, Drug Development 20+ years of proven leadership in global drug development Development Team Leader for four globally marketed products 3
5 Experienced Leadership Scientific Advisory Board Nathaniel Katz, M.D. (Chair) Global PHN Expert Renu Gupta, M.D. Renowned Antiviral Academic Carol L. Brosgart, M.D. Tenofovir Developer Richard Whitley, M.D. Herpes Virus Expert Board of Directors Gary Jacob, Ph.D. (Chair) CEO, Synergy Pharmaceuticals John P. Brancaccio, CPA CFO, Accelerated Technologies Timothy M. Block, Ph.D. Hepatitis B Foundation, Co-Founder and President Arnold S. Lippa, Ph.D. Chair and CSO, RespireRX Pharmaceuticals 4
6 Global Antiviral Market $38 billion (2013) Projected to grow to $44 billion by 2018 Well-Served Segments Human Immunodeficiency Virus (HIV) Hepatitis C (HCV) Seasonal Flu Focused on high-need segments Potential to capture expanding markets Poorly-Served Segments Hepatitis B (HBV) Herpes Zoster Virus (HZV) Respiratory Syncytial Virus (RSV) Herpes Simplex Virus (HSV) 5
7 HBV Market Opportunity 350 million chronic HBV patients worldwide 15.4%* growth in chronic HBV patients in the U.S. through thousand Ref. 1 Ref. 2 Ref. 3 HBV-related deaths in World Health Organization (WHO) 2 DataMonitor Lavancy 2004 HBV-related ESLD or HCC are responsible for > million deaths per year and currently represent 5% to 10% of cases of liver transplantation US is the largest individual market w/ highest absolute growth Limited efficacy of current antiviral treatments highlights need for new therapeutic tools for chronic HBV treatment Ref. 4 *European Growth in Chronic HBV Cases UK France Spain 10.3% 9.2% 7.5% 4 DataMonitor
8 Factors Driving Selection of Direct- Acting HBV Therapies and US Sales Relative Importance of Factors Efficacy (potency) Barrier to resistance (durability) Safety & tolerability 2014 U.S. Sales of Current HBV Drugs Ref. 4 Nucleos(t)ide Immunomodulator Baraclude Epivir Hepsera Tyzeka Viread Total Pegasys $303.1M $3.6M $31.2M $96.8M $392.2M $929.9M $103M *Nucleos(t)ide Analogs 4 BioMed Tracker 7
9 Hepatitis B Portfolio Highlights Two Candidates with Best-in-class Potency Complementary Mechanisms of Action Derived from Proven Antiviral Compounds CMX157 Differentiated Profile Lipid prodrug of successful antiviral drug tenofovir (TFV) 97-fold more active than TFV against HBV in in vitro studies At least as potent as tenofovir alafenamide (TAF) Phase 1b/2a study ongoing Drug detected in blood at 5mg dose Phase 2 is head-to-head vs. Viread Composition of matter coverage to 2031 CRV431 Differentiated Profile Next-gen, non-immunosuppressive cyclophilin inhibitor Best-in-class potency, optimized selective index Interrupts HBV at multiple points Strong Preclinical Profile Blocks HBV entry into liver cells in vitro Reduces HBV DNA without toxicity; prevents liver fibrosis in vivo Suppresses HBsAg and HBeAg in vitro Composition of matter coverage to
10 CMX157 Novel and Highly Potent Prodrug of Tenofovir Enhanced Efficacy and Safety Increased bioavailability by harnessing lipid uptake mechanisms Enhanced target tissue penetration Decreased renal and bone toxicity by reducing circulating TFV Enhanced Potency 97-fold more potent in HBV than TFV in vitro Outperforms Gilead s TAF 200-fold more potent in HIV than TFV in vitro 9
11 CMX157 Best-in-Class in vitro Potency and Safety Test Article EC 50 (nm)* EC 90 (nm)* CMX ± ± 53 TDF (Gilead s Viread ) 52.7 ± ± 427 TAF (Gilead s new HIV backbone drug) 32.4 ± ± 261 High Potency and Antiviral Activity * Mean ± standard deviation Favorable in vitro safety profile Best-in-class anti-hbv activity in vitro Equal, possibly better efficacy at low dose vs. Gilead s Viread At least as potent as Gilead s TAF (numerically more active) Results are consistent across these and other experiments performed in different laboratories Potential for improved safety profile due to less circulating TFV Low potential for QT interval cardiac arrhythmias No genotoxicity in standard assays Low potential for cytotoxicity across a large panel of cell lines from different tissues Low potential for mitochondrial toxicity 10
12 CMX157 Delays Viral Rebound in vitro All Antivirals Tested at IC 90 All Antivirals Tested at 5 nm CMX157 showed two- to three-fold reduced viral rebound compared to TAF Longer duration of action supports once-daily dosing as well as potential for increased potency and safety at lower doses Results are consistent across two different experimental conditions 11
13 CMX157 Highly Targeted to the Liver Drug Concentration in Hepatic Portal Vein vs. Systemic Circulation (+ SD) Drug Concentration in Liver (+ SD) Rapid, efficient extraction and conversion to high liver levels of the active antiviral, TFV-PP after single dose in rat Portal vein levels of CMX157 peaked at 1-3 hours and declined rapidly 86% first pass extraction Same pattern observed in liver Low systemic levels of TFV Highly targeted to liver, with accumulation in kidney and small intestine. No substantial accumulation or retention in the heart. 12
14 Ongoing CMX157 Phase 1b/2a Clinical Study Week Healthy Volunteers 2wk dose + 2wk follow-up DSMB Review CMX157 25mg qd (n=10) TDF 300mg qd (n=2) CMX157 50mg qd (n=10) TDF 300mg qd (n=2) CMX mg (n=10) TDF 300mg qd (n=2) 50mg qd (n=8) Placebo (n=2) 100mg qd (n=8) Placebo (n=2) CMX157 10mg qd (n=10) TDF 300mg qd (n=2) DSMB Review 10mg qd (n=8) Placebo (n=2) 25mg qd (n=8) Placebo (n=2) CMX157 5mg qd (n=10) TDF 300mg qd (n=2) HBV Patients 4wk dose + 4wk follow-up 5mg qd (n=8) Placebo (n=2) 13
15 505 (b)2 Pathway and CMX157 Opportunity Offers an opportunity to streamline the CMX157 Development Program by referencing Viread s select preclinical and clinical safety data Can be leveraged for New Molecular Entities (NMEs) that are based upon changes to prior drugs CMX157 and Viread share identical chemistry of their active moiety, Tenofovir Allows reliance on investigations not conducted by or for the applicant and for which the applicant has not obtained a right of reference. Potential reference of Safety Database created over last decade as well as completed preclinical toxicity and carcinogenicity studies 14
16 CMX157 Development Strategy FDA Discussions Negotiate appropriate clinical plan TFV Safety Database Access Database created over last decade Dosing studies Study prospective dosing regimens and combination therapies CMX157 Development Develop for global use 15
17 CRV431 Novel and Highly Potent Cyclophilin Inhibitor HBV-Optimized Derivative Cyclosporine A (CsA) Positioned to be leading host-targeting cyclophilin inhibitor antiviral for treatment of HBV Mechanism of Action Interrupts viral life cycle at multiple points by blocking host factor interactions Blocks HBV entry into liver cells in vitro Highlights Best-in-class potency against HBV Well-characterized safety profile for drug class Issued composition of matter and use patents through 2032 Pre-clincial Findings Good oral bioavailability; significant first pass effect Non-immunosuppressive and safe in two animal models Evidence that it may prevent liver fibrosis Reduced or eliminated production/secretion of HBsAg and HBeAg Expected to be effective against all HBV genotypes 16
18 Goal of HBV Therapy Reduction of viremia below threshold of detection of % with virtually no emergence of resistance Current: Reduction in Viremia HBV Cure Eradication of the intrahepatic replication of the virus Future: Functional Cure Suppression of HBsAg cccdna eradication 17
19 HBV Targets: Combinations Toward a Functional Cure Indirect Acting Antivirals Direct Acting Antivirals (DAAs) In use Polymerase CMX157 Potential Rnase H RNAi Capsid Inhibitors rcdna-cccdna conversion cccdna inhibitors In use Immuno- Modulatory Interferons Potential Therapeutic Vaccines Toll R agonists STING, other innate defense Interleukins, other cytokines In use CRV431 Essential Host Functions None for HBV Potential Entry Inhibitors CRV431 Exit Inhibitors ContraVir is Open to Potential Combination Partnerships With CMX157 18
20 CMX 157 and CRV431 as Prime Candidates for Combination Therapy De-risked approach to a functional cure Improvements to current treatments by combining the complementary mechanisms of action of CMX157 and CRV431 Complementary mechanisms of action against hepatitis B virus (HBV) CMX157 is adirect-acting antiviral that inhibits HBV replication CRV431 blocks HBV from entering liver cells; interrupts viral life cycle at multiple points through interactions with host molecules Both are designed specifically to improve safety and substantially enhance clinical utility of the parent molecules from which they re derived Highly potent, best-in-class antivirals 19
21 FV-100 Poised to Capture Growing Demand in PHN FV-100 Global market expansion driven by aging population Millions Number of Shingles Cases Treatable Population is Derived From US Population Minus Those Effectively Vaccinated Times The Incidence Rate % Diagnosed = 91% % Treated = 74% PHN Disease Mild to excruciating pain long after shingles rash resolves >65-70% of shingles patients suffer from PHN for 30 days or more Can last for 2-3 years Disrupts sleep, mood, work, and activities of daily living FV-100 Opportunity No FDA approved antiviral therapies for PHN No other trials ongoing with PHN endpoints Generic antivirals not labeled for PHN pain Vaccines are unreliable 20
22 FV-100: Potential to be First Approved Antiviral Therapy for PHN Pain Targeted Mechanism of Action Highly specific nucleoside analogue designed for rapid and potent inhibition of HZV replication within dorsal root ganglion Differentiated Profile Oral prodrug formulation more readily absorbed Potential improvement in dosing convenience vs. current standard of care No dose adjustment required for patients with renal insufficiency Clinically Risk-Mitigated Well tolerated with clinically meaningful reduction in PHN pain Strong IP position Composition of matter protection to
23 Herpes Zoster (Shingles) Treatments Acyclovir Valacyclovir Famciclovir FV-100 Formulation(s) IV, PO (capsule, tablet, suspension), topical PO (tablet, caplet) PO (tablets, which contain lactose) PO Dose 800mg PO 5x/day for 7-10 days 1000mg PO 3x/day for 7 days 500mg PO 3x/day for 7 days 400mg PO 1x/day for 7 days Specificity for HZV Dose adjustment for renal disease? Yes Yes Yes No Current antivirals can speed lesion healing and resolution of pain but they do not reliably prevent the onset of PHN 22
24 FV-100 is Market-Differentiated Annual Prescriptions & Market Share Valacyclovir 11.6M 57% Acyclovir 8.0M 39% Famciclovir 0.8 M 4% 20 million prescriptions annually (U.S.) 5.8% Rx growth since 2010 (annualized average) Majority of prescriptions are generic Highly Competitive Profile: Opportunity for QD dosing Efficacy profile superior to valacyclovir Acute pain: 25-30% reduction Sub-acute pain: significant reduction PHN: significant risk reduction Safety profile comparable to valacyclovir Source: NPA Data - 12 months ending 12/31/2012 Drug 2014 Global Sales Acyclovir $1.113B Valacyclovir $802M Famciclovir $207M Drug 2014 U.S. Sales Acyclovir $471M Valacyclovir $359M Famciclovir $27M 23
25 FV-100 Clinical Highlights Demonstrated Safety and Efficacy >350 patients treated with FV-100 Phase 1 (N=3) and Phase 2 (N=1) studies completed Clinically meaningful reduction in PHN occurrence vs. valacyclovir (Valtrex ) Meaningful reduction in time to resolution of clinically significant pain 8-10% reduction in narcotic use for pain control Safety similar to other antivirals Proprietary & Differentiated Rapid onset of action for quick pain relief Higher potency vs. approved agents against HZV Potential for QD dosing vs. 3-5x/day for Valtrex No dose adjustments needed for patients with renal insufficiency Proceeding to Phase 3 Pivotal Phase 3 (Study 007) 3-arm study with PHN reduction endpoint (vs. Valtrex ) 24
26 PHN Endpoint Favors FV-100 FV-100 Key Results (Study 005) % PHN at 90 days % Reduction vs. valacyclovir % Reduction vs. valacyclovir Both FV-100 arms performed better than valacyclovir at reducing the percent of patients reporting PHN pain at 90 days Secondary pain endpoints consistently favor FV-100 Pain endpoints are FV-100 dose dependent Study 007 (Phase 3) will further examine this endpoint mg 400 mg Val 25
27 FV-100 Pivotal Trial vs. Valacyclovir (Study 007) Basic Design Multi-center, randomized, double-blind, parallel-group, comparative study (N=825) Three-arms, 275 patients/arm: 1. FV mg QD 2. FV mg BID 3. Valacyclovir 1000mg TID 7-day treatment with follow up through day 120 Up to 200 US centers Goals Optimize FV-100 dose and regimen Confirm efficacy using registerable primary endpoint with commercial feasibility Focus on clinically significant PHN Primary Endpoint Proportion of patients with PHN at day 120 Key Secondary Endpoints Time to loss of acute PHN pain Other pain and quality of life assessments Safety Pharmacokinetics 26
28 Financial Metrics Share Statistics Trading Symbol NASDAQ:CTRV Stock Price (6/27/16) $1.00 Capital Structure (Current) 32.2M shares of common Common Shares O/s 32.2M 4.1M options for common 52wk Range $ $ M warrants for common 3 Month Avg. Volume 383, million shares of preferred series A Cash $6M* 120k shares of preferred series B *Does not include April 2016 closing of $7 million offering of common stock and warrants 27
29 ContraVir Value Drivers Strategic Focus Develop and commercialize novel drug treatments to improve the lives of patients suffering from chronic viral infections Experienced Leadership Significant expertise in drug development and commercialization of targeted antivirals HBV Program: Phase 1b/2a studies; advancing CRV431 into clinical Combination therapy has a greater chance of eradicating chronic infection Strong composition of matter patents for both compounds Leveraging the TFV database could open up multiple clinical options, including a 505(b)2 pathway for streamlined approval and commercialization PHN Program: Ongoing Phase 3 Trial No FDA approved antiviral therapies for PHN If drug shows 60% prevention, high chance FDA will grant 2 indicators 28
30 399 Thornall Street, 1st Floor Edison, NJ Please visit us at 29
Inarigivir ACHIEVE Trial Results and HBV Clinical Program Update. August 2, 2018
Inarigivir ACHIEVE Trial Results and HBV Clinical Program Update August 2, 2018 FORWARD LOOKING STATEMENT This presentation includes forward-looking statements within the meaning of the Private Securities
More informationIdenix Pharmaceuticals Building a Leading Antiviral Franchise. Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston
Idenix Pharmaceuticals Building a Leading Antiviral Franchise Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston Safe Harbor This presentation includes forward-looking statements
More informationA Leading HBV Therapeutics Company. Corporate Overview August 2017
A Leading HBV Therapeutics Company Corporate Overview August 2017 NASDAQ: ABUS www.arbutusbio.com Forward Looking Statements This presentation contains forward-looking statements within the meaning of
More informationEfficient Liver Targeting and Uptake by Novel Tenofovir Prodrug, CMX157, For the Treatment of Hepatitis B
Efficient Liver Targeting and Uptake by Novel Tenofovir Prodrug, CMX157, For the Treatment of Hepatitis B R Rush 1, J Greytok 2, T Matkovits 2, R Driz 2, JZ Sullivan-Bólyai 2, and D Standring 3 1 Allon
More informationUBS Global Healthcare Conference May 19, 2014
UBS Global Healthcare Conference May 19, 2014 Safe Harbor Statement This presentation may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section
More informationDynavax Corporate Presentation
Dynavax Corporate Presentation Forward-Looking Statements This presentation contains forward-looking statements, including statements regarding our HEPLISAV-B TM regulatory submissions, product profile,
More informationRichard Colonno Executive Vice President and Chief Scientific Officer of Virology Operations
Targeting HBV Core Protein to Clear Infection and Achieve Higher Cure Rates Richard Colonno Executive Vice President and Chief Scientific Officer of Virology Operations 1 CAUTIONARY NOTE REGARDING FORWARD-
More informationTargeting HBV Core Protein to Clear Infection and Achieve Higher Cure Rates
Targeting HBV Core Protein to Clear Infection and Achieve Higher Cure Rates Richard Colonno Executive Vice President and Chief Scientific Officer of Virology Operations 1 CAUTIONARY NOTE REGARDING FORWARD-LOOKING
More informationDiscovery of Potent, Highly Selective, Broad Spectrum Antivirals
Discovery of Potent, Highly Selective, Broad Spectrum Antivirals Fred Hutch/Merck Infectious Disease Summit May 10, 2018 Sam Lee, Ph.D. 1 Forward Looking Statements This presentation contains forward-looking
More informationPierre Legault CEO June 2, 2014
April 2012 Pierre Legault CEO June 2, 2014 Forward Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases, these forward-looking
More informationRESEARCH AND INNOVATION AT LUTRAN
2 innovation RESEARCH AND INNOVATION AT LUTRAN LuTran Inc. is a dynamic, innovation driven pharmaceutical research company located in the heart of Silicon Valley, where we push the boundaries of medical
More informationBioCryst Pharmaceuticals
BioCryst Pharmaceuticals Jefferies 2010 Global Life Sciences Conference New York Stuart Grant Senior Vice President & Chief Financial Officer Rob Bennett Executive Director, Investor Relations & Business
More informationM (SAPPHIRE-II)
PRESS RELEASE AbbVie Demonstrates 96 percent SVR 12 in its Phase III Study of Treatment- Experienced Patients with Genotype 1 Hepatitis C Results further confirm phase II studies, with consistent virologic
More informationIdenix Pharmaceuticals Building a Leading Antiviral Franchise
Idenix Pharmaceuticals Building a Leading Antiviral Franchise Cowen and Company 7 th Annual Global Healthcare Conference November 7, 2006 Jean-Pierre Sommadossi, Ph.D. Chairman and CEO Safe Harbor This
More informationRNAi Therapy for Chronic HBV Infection
RNAi Therapy for Chronic HBV Infection Bill Symonds, PharmD Chief Development Officer October 2017 NASDAQ: ABUS www.arbutusbio.com Forward Looking Statements This presentation contains forward-looking
More informationForward Looking Statements
Antiviral Therapies Forward Looking Statements This presentation contains forward-looking statements, including the timing of our drug development programs. Risks include delays in manufacturing created
More informationForward Looking Statements
Slide title Forward Looking Statements This presentation may contain forward looking statements with respect to the financial condition, results and business achievements/performance of Biotron Limited
More informationLEERINK GLOBAL HEALTHCARE CONFERENCE. Marino Garcia EVP, Chief Strategy Officer February 15, 2017
LEERINK GLOBAL HEALTHCARE CONFERENCE Marino Garcia EVP, Chief Strategy Officer February 15, 2017 SAFE HARBOR STATEMENT This presentation and any statements made for and during any presentation or meeting
More informationSavient's Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference
Savient's Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference EAST BRUNSWICK, N.J., Oct 27, 2008 /PRNewswire-FirstCall
More informationForward Looking Statements
Antiviral Therapies Forward Looking Statements This presentation contains forward-looking statements, including the timing of our drug development programs. Risks include delays in manufacturing created
More informationAvenue Therapeutics, Inc. August 2016
Avenue Therapeutics, Inc. August 2016 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward looking statements within the meaning of the safe
More informationAvenue Therapeutics, Inc. September 2016
Avenue Therapeutics, Inc. September 2016 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward looking statements within the meaning of the
More informationAviragen Therapeutics, Inc. and Vaxart Inc. Joint Conference Call UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES
Aviragen Therapeutics, Inc. and Vaxart Inc. Joint Conference Call UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES October 30, 2017 Safe Harbor This presentation contains forward-looking statements about
More informationAVENUE THERAPEUTICS, INC. NASDAQ: ATXI JANUARY 2018
AVENUE THERAPEUTICS, INC. NASDAQ: ATXI JANUARY 2018 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward-looking statements within the meaning
More informationN A S D A Q : E V F M
N A S D A Q : E V F M Jefferies Global Healthcare Conference June 7, 2018 Disclaimer This presentation contains forward looking statements within the meaning of The Private Securities Litigation Reform
More informationDavid Zaccardelli, PharmD Chief Executive Officer. J.P. Morgan 37 th Annual Healthcare Conference January 8, 2019
David Zaccardelli, PharmD Chief Executive Officer J.P. Morgan 37 th Annual Healthcare Conference January 8, 2019 Disclaimer Certain information contained in this presentation relates to or is based on
More informationCytomegalovirus (CMV) Infections - Pipeline Assessment and Market Forecasts to 2019
Reference Code: GDHC504PRT Publication Date: January 2013 Cytomegalovirus Infections: Key Metrics in Seven Major Pharmaceutical Markets 2012 Epidemiology* Prevalent population (CMV prevalent cases in general
More informationAvenue Therapeutics, Inc. May 2017
Avenue Therapeutics, Inc. May 2017 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward looking statements within the meaning of the safe
More informationNYSE AMER: MTNB. MAT9001 OVERVIEW. September 2018
NYSE AMER: MTNB www.matinasbiopharma.com MAT9001 OVERVIEW September 2018 1 Forward Looking Statement This presentation contains "forward-looking statements" within the meaning of the Private Securities
More informationSynergy Pharmaceuticals TRULANCE (Plecanatide) Receives U.S. FDA Approval for the Treatment of Adults with Chronic Idiopathic Constipation
January 19, 2017 Synergy Pharmaceuticals TRULANCE (Plecanatide) Receives U.S. FDA Approval for the Treatment of Adults with Chronic Idiopathic Constipation NEW YORK--(BUSINESS WIRE)-- Synergy Pharmaceuticals
More informationForward Looking Statements
Antiviral Therapies Forward Looking Statements This presentation contains forward-looking statements, including the timing of our drug development programs. Risks include delays in manufacturing created
More informationImmunocore and MedImmune announce new collaboration to conduct immuno-oncology combination trials in melanoma
PRESS RELEASE IMMUNOCORE LIMITED Immunocore and MedImmune announce new collaboration to conduct immuno-oncology combination trials in melanoma (Oxford, UK, 16 April 2015) Immunocore Limited, a world-leading
More informationInnovation In Ophthalmics
Innovation In Ophthalmics Ophthalmic Innovation Summit @ AAO 2018 October 25, 2018 Mark Iwicki Chairman & CEO, Kala Pharmaceuticals Disclaimers and Notices This presentation contains forward-looking statements
More informationInvestor presentation. Bioshares Biotech Summit July 2017
Investor presentation Bioshares Biotech Summit 2017 22 July 2017 1 Disclaimer Some of the information in this presentation may refer to Dimerix Limited ( Dimerix or the Company ) based on information available
More informationInnovation In Ophthalmology
Innovation In Ophthalmology INVELTYS TM Approval August 2018 Disclaimers and Notices This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform
More informationHepatitis B Virus. Taylor Page PharmD Candidate 2019 February 1, 2019
Hepatitis B Virus Taylor Page PharmD Candidate 2019 February 1, 2019 Epidemiology 3218 cases of acute HBV reported in 2016 847,000 non-institutionalized persons living with chronic HBV in 2011-2012 Viral
More informationInvestor Presentation June 2012 NASDAQ: CEMI
Investor Presentation June 2012 NASDAQ: CEMI Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act
More informationJP Morgan Healthcare Conference. January 8, 2007
JP Morgan Healthcare Conference January 8, 2007 Safe Harbor Statement Except for the historical information set forth herein, the matters set forth in this presentation,including without limitation statements
More informationAVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC
FOR IMMEDIATE RELEASE AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC - Tivozanib is the First Agent to Demonstrate Greater than One Year
More informationAVEO and Astellas Report Final Overall Survival Results from TIVO-1
AVEO and Astellas Report Final Overall Survival Results from TIVO-1 - Median Overall Survival of 28.8 Months Reported for Tivozanib in Patients with Advanced Kidney Cancer - CAMBRIDGE, Mass. and TOKYO,
More informationHepatitis B New Therapies
Hepatitis B New Therapies Richard K. Sterling, MD, MSc, FACP, FACG, FAASLD, AGAF VCU Hepatology Professor of Medicine Chief, Section of Hepatology Fellowship Director, Transplant Hepatology Virginia Commonwealth
More informationDatamonitor Healthcare Pharma intelligence. GlaxoSmithKline: Company Analysis
Datamonitor Healthcare Pharma intelligence GlaxoSmithKline: Company Analysis OVERVIEW Latest Earnings Review Q2 2018 [27 July 2018] Click to view analysis Latest Forecast Update Q2 2018 [2 August 2018]
More informationForward-Looking Statements
Investor Presentation May 2012 Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended.
More informationADAPTIMMUNE INVESTOR PRESENTATION. August 2016
ADAPTIMMUNE INVESTOR PRESENTATION August 2016 DISCLAIMER This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),
More informationCorporate Presentation May Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers
Corporate Presentation May 2016 Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers Forward-looking statements / safe harbor This presentation and the accompanying oral commentary contain
More informationFebruary 23, Q4 and Year-End 2016 Financial Results
February 23, 2017 Q4 and Year-End 2016 Financial Results 2 RETHINKING CNS Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Jim Doherty, Ph.D.,
More information34 th Annual J.P. Morgan Healthcare Conference
JANUARY 2016 34 th Annual J.P. Morgan Healthcare Conference [ 1 ] Forward Looking Statements SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS In addition to historical information, this presentation contains
More informationFor personal use only
Australian Securities Exchange Limited Companies Announcements Office SYDNEY 4 April, 2012 New Australian Drug Developer Lists on ASX Key points Growth-focused Australian drug and therapeutic development
More informationCORPORATE PRESENTATION
CORPORATE PRESENTATION June 2017 FORWARD LOOKING SAFE HARBOR STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More informationPresentation #: OP221
Pharmacokinetics, Safety and Tolerability of, a Novel Prodrug of Tenofovir, Administered as Ascending Multiple Doses to Healthy Volunteers and HBV-Infected Subjects Presentation #: OP22 Tawesak Tanwandee,
More informationRespireRx Pharmaceuticals Inc. Executives Presenting at the International Cannabinoid Derived Pharmaceuticals Summit
RespireRx Pharmaceuticals Inc. Executives Presenting at the International Cannabinoid Derived Pharmaceuticals Summit December 11 12, 2018 Workshops, December 10, 2018 The Revere Hotel 200 Stuart St., Boston,
More informationCloudbreak. January Cidara Therapeutics
Cloudbreak January 2019 Cidara Therapeutics 2019 0 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements within the meaning of the Private Securities
More informationDARA Reports Year-End 2012 Financial Results
April 1, 2013 DARA Reports Year-End 2012 Financial Results Company Provides a Commercial Portfolio and Development Pipeline Business Update RALEIGH, NC -- (MARKETWIRE) -- 04/01/13 -- DARA BioSciences,
More informationNovel Bispecific Antibodies for Treating Hepatitis B Virus Infection. Dr. Felix Bohne
Novel Bispecific Antibodies for Treating Hepatitis B Virus Infection Dr. Felix Bohne Munich, 11.05.2015 Consequences of Hepatitis B Virus 2 Global prevalence of Hepatitis B (percentage of population per
More informationHepatitis B Treatment Pearls. Agenda
Hepatitis B Treatment Pearls Fredric D. Gordon, MD Vice Chair Dept. of Transplantation and Hepatobiliary Diseases Lahey Hospital & Medical Center Associate Professor of Medicine Tufts Medical School Boston,
More informationScottish Medicines Consortium
Scottish Medicines Consortium tenofovir disoproxil (as fumarate), 245 mg film-coated tablet (Viread ) No. (479/08) Gilead Sciences 06 June 2008 The Scottish Medicines Consortium has completed its assessment
More informationA Leading HBV Therapeutics Company Corporate Overview March 2018
A Leading HBV Therapeutics Company Corporate Overview March 2018 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act
More informationExpertise in Drug Discovery for Respiratory Viral Diseases
Expertise in Drug Discovery for Respiratory Viral Diseases Nasdaq: BOTA June 2014 Safe Harbor This presentation contains forward-looking statements about Biota Pharmaceuticals, Inc. and its business, business
More informationIntercell and Novartis form world leading strategic partnership to drive vaccines innovation
Intercell and Novartis form world leading strategic partnership to drive vaccines innovation Alliance creates opportunity for two strong innovators to combine development efforts in attractive areas Intercell
More informationCorporate Presentation January 2019 NASDAQ: CTRV NASDAQ: CTRV
1 Corporate Presentation January 2019 Forward-Looking Statements 2 This presentation may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E
More informationJuly, ArQule, Inc.
July, 2012 Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to clinical
More informationCorporate Presentation January 2019
Corporate Presentation January 2019 1 Forward-Looking Statement Disclosure Any statements made in this presentation relating to future financial or business performance, conditions, plans, prospects, trends,
More informationBIOTRON TO PRESENT AT AUSTRALIA BIOTECH INVEST 2013
Level 2, 66 Hunter Street Sydney NSW 2000 Tel: (61-2) 9300 3344 Fax: (61-2) 9221 6333 E-mail: pnightingale@biotron.com.au Website: www.biotron.com.au 28 October 2013 The Manager Companies ASX Limited 20
More informationAssembly Biosciences, Inc. Corporate Presentation. March 2018 Nasdaq: ASMB
Assembly Biosciences, Inc. Corporate Presentation March 2018 Nasdaq: ASMB Cautionary Note Regarding Forward-Looking Statements The information in this presentation contains estimates and other forward-looking
More informationIdenix Pharmaceuticals: Building a Leading Antiviral Franchise. Jean-Pierre Sommadossi Chairman and Chief Executive Officer Spring 2006
Idenix Pharmaceuticals: Building a Leading Antiviral Franchise Jean-Pierre Sommadossi Chairman and Chief Executive Officer Spring 2006 Safe Harbor This presentation includes forward-looking statements
More informationArQule Jefferies Global Healthcare Conference June 2015
ArQule Jefferies Global Healthcare Conference June 2015 1 ArQule Corporate Update Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning
More informationCorporate Overview H.C. Wainwright & Co. Global Life Sciences Conference April 10, 2018 Douglas M. Fambrough, CEO Jack Green, CFO
NASDAQ: DRNA Corporate Overview H.C. Wainwright & Co. Global Life Sciences Conference April 10, 2018 Douglas M. Fambrough, CEO Jack Green, CFO Forward looking statements This information may contain projections
More informationMerrill Lynch's Global Pharmaceutical, Biotechnology, and Medical Device Conference. February 7, 2007
Merrill Lynch's Global Pharmaceutical, Biotechnology, and Medical Device Conference February 7, 2007 Information related to forward-looking statements This presentation includes forward-looking statements
More informationLION. Corporate Presentation June 2016 BIOTECHNOLOGIES. Leadership & Innovation in Oncology
LION BIOTECHNOLOGIES Leadership & Innovation in Oncology Corporate Presentation June 2016 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private
More informationJefferies Healthcare Conference
Jefferies Healthcare Conference June 7, 2016 NASDAQ: CHMA Forward-Looking Statements These slides contain forward-looking statements and information. The use of words such as may, might, will, should,
More informationBobby W. Sandage, Jr., PhD President & Chief Executive Officer. Lazard Capital Markets 8 th Annual Healthcare Conference
Bobby W. Sandage, Jr., PhD President & Chief Executive Officer Lazard Capital Markets 8 th Annual Healthcare Conference Statements in this presentation that are not descriptions of historical facts are
More informationPRESENTATION TO INVESTORS. I attach a PowerPoint presentation as presented by Biotron Limited's CEO, Dr Michelle Miller, to investors today.
Level 2, 66 Hunter Street Sydney NSW 2000 Tel: (61-2) 9300 3344 Fax: (61-2) 9221 6333 E-mail: pnightingale@biotron.com.au Website: www.biotron.com.au 11 November 2010 The Manager Companies ASX Limited
More informationCytoDyn Announces Initiation of Metastatic Triple Negative Breast Cancer Trial and Reiterates Phase 3 Goal in Cancer
November 26, 2018 CytoDyn Announces Initiation of Metastatic Triple Negative Breast Cancer Trial and Reiterates Phase 3 Goal in Cancer VANCOUVER, Washington, Nov. 26, 2018 (GLOBE NEWSWIRE) -- CytoDyn Inc.
More informationTwo-stage study designed to evaluate tolerability and efficacy of pracinostat combined with azacitidine in patients with high and very high risk MDS
Helsinn Group and MEI Pharma Announce First Patient Dosed in Phase 2 Dose-Optimization Study of Pracinostat and Azacitidine in Myelodysplastic Syndrome Two-stage study designed to evaluate tolerability
More informationIntron A Hepatitis B. Intron A (interferon alfa-2b) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.01 Subject: Intron A Hepatitis B Page: 1 of 7 Last Review Date: November 30, 2018 Intron A Hepatitis
More informationR&D Webinar: Product Pipeline Update
R&D Webinar: Product Pipeline Update Dr. Mark Murray, President & CEO Dr. Mark Kowalski, Chief Medical Officer Dr. Ian MacLachlan, Chief Scientific Officer Ian Mortimer, Executive Vice President Bruce
More informationAugust 7, Q Financial Results
August 7, 2018 Q2 2018 Financial Results 1 Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Steve Kanes, M.D., Ph.D., Chief Medical Officer
More informationVICAL INC FORM 8-K. (Current report filing) Filed 11/02/06 for the Period Ending 11/02/06
VICAL INC FORM 8-K (Current report filing) Filed 11/02/06 for the Period Ending 11/02/06 Address 10390 PACIFIC CENTER COURT. SAN DIEGO, CA 92121-4340 Telephone 858-646-1100 CIK 0000819050 Symbol VICL SIC
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer June 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results may
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer January 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results
More informationDrug Class Monograph
Drug Class Monograph Class: Chronic Hepatitis B Drug: Baraclude (entecavir), Epivir (lamivudine), Hepsera (adefovir), Intron A (interferon alfa- 2b), Pegasys (peginterferon alfa-2a), Tyzeka (telbivudine),
More informationDealdoc. Licensing, development and marketing agreement for Relenza. Glaxo Wellcome GlaxoSmithKline Biota. Sep
Dealdoc Licensing, development and marketing agreement for Relenza Glaxo Wellcome GlaxoSmithKline Biota Sep 04 2000 Licensing, development and marketing agreement for Relenza Glaxo Wellcome Companies:
More informationAcasti Pharma Provides Business Update for the Third Quarter of Fiscal 2019
Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2019 Planned Enrollment targets achieved in both TRILOGY studies with over 74% of patients randomized at more than 150 clinical sites
More informationOragenics Shareholder Update
January 4, 2017 Oragenics Shareholder Update Advances Drug Development Programs Focused on Conditions with Significant Unmet Medical Needs TAMPA, Fla.--(BUSINESS WIRE)-- Oragenics, Inc. (NYSE MKT:OGEN.BC),
More information1Q2018 EARNINGS CALL MAY 7, 2018
1Q2018 EARNINGS CALL MAY 7, 2018 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements and information within the meaning of the Private Securities
More informationCorporate Presentation
Corporate Presentation January 2019 2018 Chembio. All Rights Reserved. # 2019 Chembio. All Rights Reserved. Page 1 Safe Harbor Statement Statements contained herein that are not historical facts are forward-looking
More informationNovan Announces Promising Clinical Results with SB414
Novan Announces Promising Clinical Results with SB414 In the recently completed Phase 1b trial for atopic dermatitis, clinical efficacy measures were highly correlated with critical and disease-relevant
More informationOTEZLA (Apremilast) Showed Meaningful Improvements in Clinical and Quality of Life Measures of Psoriasis Beyond Those Captured by Assessing Skin Alone
OTEZLA (Apremilast) Showed Meaningful Improvements in Clinical and Quality of Life Measures of Psoriasis Beyond Those Captured by Assessing Skin Alone Patients with moderate to severe plaque psoriasis
More informationMedivir at. Avanza s Företagsdag 10 december Lars Adlersson, CEO Börje Darpö, VP Development
Medivir at Avanza s Företagsdag 10 december 2008 Lars Adlersson, CEO Börje Darpö, VP Development Medivir contact rein.piir@medivir.se www.medivir.com Medivir Key achievements 2008 Strong phase IIa data
More informationJefferies Healthcare Conference. June 25, 2008
Jefferies Healthcare Conference June 25, 2008 Safe Harbor Statement Except for the historical information set forth herein, the matters set forth in this presentation,including without limitation statements
More informationBroad and clinically important benefits beyond the initial registrational endpoints are now reported.
Biohaven Announces Robust Clinical Data with Single Dose Rimegepant That Defines Acute and Durable Benefits to Patients: The First Oral CGRP Receptor Antagonist to Deliver Positive Data on Pain Freedom
More informationInvestors Update: Abuse-Deterrent d-amphetamine Immediate Release (ADAIR) for ADHD
Investors Update: Abuse-Deterrent d-amphetamine Immediate Release (ADAIR) for ADHD February 7, 2017 1 Forward-Looking Statements This presentation contains forward-looking statements within the meaning
More informationSlides are the property of the author and AASLD. Permission is required from both AASLD and the author for reuse.
Inarigivir Demonstrates Potent Dose Dependent Anti-Viral Activity in HBV Treatment-Naïve Patients: Role of HBeAg Status and Baseline HBsAg in Anti-Viral Response MF Yuen, M. Elkhashab, CY Chen, YF Chen,
More informationDetermined to realize a future in which people with cancer live longer and better than ever before Q Conference Call
Reimagining Cancer Treatment Determined to realize a future in which people with cancer live longer and better than ever before Q1 2016 Conference Call 1 Forward-Looking Statements Disclosure This presentation
More informationRNA Interference: A New Tool in the Toolbox for Treatment of HBV. Discovery On Target Senior Director, Research 25 September 2017
RNA Interference: A New Tool in the Toolbox for Treatment of HBV Amy Lee Discovery On Target Senior Director, Research 25 September 2017 Arbutus Biopharma Boston, MA NASDAQ: ABUS www.arbutusbio.com Chronic
More informationHepatitis B Prior Authorization Policy
Hepatitis B Prior Authorization Policy Line of Business: Medi-Cal P&T Approval Date: November 15, 2017 Effective Date: January 1, 2018 This policy has been developed through review of medical literature,
More informationMOLOGEN AG Jefferies 2014 London Healthcare Conference
Jefferies 2014 London Healthcare Conference Dr. Matthias Schroff Chief Executive Officer London 20 November 2014 V1-6 Disclaimer Certain statements in this presentation contain formulations or terms referring
More informationInovio Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationFuture Leaders in the Biotech Industry. Lee Bendekgey, SVP, CFO & General Counsel April 7, 2005
Future Leaders in the Biotech Industry Lee Bendekgey, SVP, CFO & General Counsel April 7, 2005 Safe Harbor This presentation contains "forward-looking statements" regarding potential use of Nuvelo clinical
More informationForward-looking Statements
NASDAQ:CNAT Forward-looking Statements This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements
More information